View in EDS

Real-world postprogression outcomes after first-line treatment with ribociclib plus aromatase inhibitor versus aromatase inhibitor alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States of America.

Saved in:
Bibliographic Details
Title: Real-world postprogression outcomes after first-line treatment with ribociclib plus aromatase inhibitor versus aromatase inhibitor alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States of America.
Authors: Hart L; Department of Cancer Medicine, Wake Forest University School of Medicine, Winston-Salem, USA. Electronic address: llhart@flcancer.com., Rugo HS; Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, USA., Sharma P; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Westwood, USA., Sammons S; Breast Oncology Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA., Gadi VK; Division of Hematology and Oncology, Department of Medicine, University of Illinois College of Medicine and University of Illinois Cancer Center, Chicago, USA., Mavros P; KREDHERA, LLC, Hampton, USA., Kaur M; Flatiron Health, New York, USA., Boualam N; Flatiron Health, New York, USA., Keane C; Flatiron Health, New York, USA., Sopher G; Novartis Pharmaceuticals Corporation, East Hanover, USA., Pathak P; Novartis Pharmaceuticals Corporation, East Hanover, USA., Tarantino P; Department of Medicine, Harvard Medical School, Boston, USA.
Source: ESMO open [ESMO Open] 2026 Jul; Vol. 11 (7), pp. 108243. Date of Electronic Publication: 2026 Jul 07.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42413325
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Real-world postprogression outcomes after first-line treatment with ribociclib plus aromatase inhibitor versus aromatase inhibitor alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States of America.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Hart+L%22">Hart L</searchLink>; Department of Cancer Medicine, Wake Forest University School of Medicine, Winston-Salem, USA. Electronic address: llhart@flcancer.com.<br /><searchLink fieldCode="AU" term="%22Rugo+HS%22">Rugo HS</searchLink>; Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, USA.<br /><searchLink fieldCode="AU" term="%22Sharma+P%22">Sharma P</searchLink>; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Westwood, USA.<br /><searchLink fieldCode="AU" term="%22Sammons+S%22">Sammons S</searchLink>; Breast Oncology Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.<br /><searchLink fieldCode="AU" term="%22Gadi+VK%22">Gadi VK</searchLink>; Division of Hematology and Oncology, Department of Medicine, University of Illinois College of Medicine and University of Illinois Cancer Center, Chicago, USA.<br /><searchLink fieldCode="AU" term="%22Mavros+P%22">Mavros P</searchLink>; KREDHERA, LLC, Hampton, USA.<br /><searchLink fieldCode="AU" term="%22Kaur+M%22">Kaur M</searchLink>; Flatiron Health, New York, USA.<br /><searchLink fieldCode="AU" term="%22Boualam+N%22">Boualam N</searchLink>; Flatiron Health, New York, USA.<br /><searchLink fieldCode="AU" term="%22Keane+C%22">Keane C</searchLink>; Flatiron Health, New York, USA.<br /><searchLink fieldCode="AU" term="%22Sopher+G%22">Sopher G</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, USA.<br /><searchLink fieldCode="AU" term="%22Pathak+P%22">Pathak P</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, USA.<br /><searchLink fieldCode="AU" term="%22Tarantino+P%22">Tarantino P</searchLink>; Department of Medicine, Harvard Medical School, Boston, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101690685%22">ESMO open</searchLink> [ESMO Open] 2026 Jul; Vol. 11 (7), pp. 108243. <i>Date of Electronic Publication: </i>2026 Jul 07.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101690685 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2059-7029 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220597029%22">20597029 </searchLink><i>NLM ISO Abbreviation: </i>ESMO Open <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42413325
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.esmoop.2026.108243
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 108243
    Titles:
      – TitleFull: Real-world postprogression outcomes after first-line treatment with ribociclib plus aromatase inhibitor versus aromatase inhibitor alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States of America.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Hart L
      – PersonEntity:
          Name:
            NameFull: Rugo HS
      – PersonEntity:
          Name:
            NameFull: Sharma P
      – PersonEntity:
          Name:
            NameFull: Sammons S
      – PersonEntity:
          Name:
            NameFull: Gadi VK
      – PersonEntity:
          Name:
            NameFull: Mavros P
      – PersonEntity:
          Name:
            NameFull: Kaur M
      – PersonEntity:
          Name:
            NameFull: Boualam N
      – PersonEntity:
          Name:
            NameFull: Keane C
      – PersonEntity:
          Name:
            NameFull: Sopher G
      – PersonEntity:
          Name:
            NameFull: Pathak P
      – PersonEntity:
          Name:
            NameFull: Tarantino P
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2026 Jul
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2059-7029
          Numbering:
            – Type: volume
              Value: 11
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: ESMO open
              Type: main
ResultId 1